Yoshida Shiomi, Tsuyuguchi Kazunari, Kobayashi Takehiko, Tomita Motohisa, Inoue Yoshikazu, Hayashi Seiji, Suzuki Katsuhiro
Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka 591-8555, Japan.
Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka 591-8555, Japan.
J Med Microbiol. 2018 Jan;67(1):74-82. doi: 10.1099/jmm.0.000661. Epub 2017 Dec 11.
Macrolide susceptibility differs between subspecies in the Mycobacterium abscessus complex, likely due to differences in erm(41) sequevars. Patients with M. abscessus complex infection generally show poor clinical outcomes in response to antibiotic treatment. Here, the association between genotype and treatment outcome was investigated.
We collected 69 isolates from 35 patients with non-cystic fibrosis bronchiectasis: 24 had M. abscessus complex lung disease and non-cystic fibrosis bronchiectasis, and 11 were colonized. Outcome analysis was performed in the 24 infected patients. Molecular analyses, including erm(41) and rrl sequencing, and variable-number tandem-repeat (VNTR) analysis of 69 isolates, from 24 infected and 11 colonized patients, were performed to elucidate the influence of genotype on antibiotic susceptibility.
Among the 24 patients, 18 (14 infected with M. abscessus subsp. abscessus and 4 with M. abscessus subsp. massiliense) showed unfavourable outcomes; six (three infected with M. abscessus subsp. abscessus and three with M. abscessus subsp. massiliense) exhibited favourable outcomes. Patients with unfavourable outcomes showed acquired clarithromycin resistance (33.3 vs 0 %), mixed sequevars (38.9 vs 16.7 %) and differing VNTR patterns between initial and serial isolates (33.3 vs 16.7 %). In contrast, in the 11 colonized patients, M. abscessus subsp. abscessus C28 (sequevar 02) and M. abscessus subsp. massiliense were the most prevalent subspecies.
Patients infected with multiple sequevars and genotypes were more likely to exhibit treatment failure and/or recurrence. The precise identification of subspecies and analyses of mycobacterial characteristics may help to predict treatment outcomes in patients with M. abscessus complex lung disease.
脓肿分枝杆菌复合群中亚种间的大环内酯类药物敏感性存在差异,可能是由于erm(41)序列变异体不同所致。脓肿分枝杆菌复合群感染患者对抗生素治疗的临床反应通常较差。在此,研究了基因型与治疗结果之间的关联。
我们从35例非囊性纤维化支气管扩张患者中收集了69株分离株:24例患有脓肿分枝杆菌复合群肺病和非囊性纤维化支气管扩张,11例为定植菌。对24例感染患者进行了结果分析。对来自24例感染患者和11例定植患者的69株分离株进行了分子分析,包括erm(41)和rrl测序以及可变数目串联重复序列(VNTR)分析,以阐明基因型对抗生素敏感性的影响。
在24例患者中,18例(14例感染脓肿分枝杆菌脓肿亚种,4例感染脓肿分枝杆菌马赛亚种)预后不佳;6例(3例感染脓肿分枝杆菌脓肿亚种,3例感染脓肿分枝杆菌马赛亚种)预后良好。预后不佳的患者表现出获得性克拉霉素耐药(33.3%对0%)、混合序列变异体(38.9%对16.7%)以及初始分离株和连续分离株之间不同的VNTR模式(33.3%对16.7%)。相比之下,在11例定植患者中,脓肿分枝杆菌脓肿亚种C28(序列变异体02)和脓肿分枝杆菌马赛亚种是最常见的亚种。
感染多种序列变异体和基因型的患者更有可能出现治疗失败和/或复发。准确鉴定亚种并分析分枝杆菌特征可能有助于预测脓肿分枝杆菌复合群肺病患者的治疗结果。